

# The STEP (Safety and Toxicity of Excipients for Paediatric) assessment study

International Journal of Pharmaceutics

435, 101-111

DOI: [10.1016/j.ijpharm.2012.05.004](https://doi.org/10.1016/j.ijpharm.2012.05.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: Proceedings from the Second Workshop on Pediatric Formulations. <i>Clinical Therapeutics</i> , 2012, 34, S1-S10.	1.1	26
2	Educational Paper: Formulation-related issues in pediatric clinical pharmacology. <i>European Journal of Pediatrics</i> , 2013, 172, 717-720.	1.3	43
3	The STEP (Safety and Toxicity of Excipients for Paediatrics) database: Part 2 – The pilot version. <i>International Journal of Pharmaceutics</i> , 2013, 457, 310-322.	2.6	66
4	Pediatric clinical pharmacology: an introduction to a series of educational papers. <i>European Journal of Pediatrics</i> , 2013, 172, 289-292.	1.3	2
5	Neonates need tailored drug formulations. <i>World Journal of Clinical Pediatrics</i> , 2013, 2, 1.	0.6	9
6	Persistent pharmacokinetic challenges to pediatric drug development. <i>Frontiers in Genetics</i> , 2014, 5, 281.	1.1	19
7	Neonatal Formulations and Additives. <i>Pediatric and Adolescent Medicine</i> , 2015, , 41-57.	0.4	2
8	Paediatric oral biopharmaceutics: Key considerations and current challenges. <i>Advanced Drug Delivery Reviews</i> , 2014, 73, 102-126.	6.6	104
9	Pediatric Formulations. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , .	0.2	10
10	Pediatric Drug Formulations: A Review of Challenges and Progress. <i>Pediatrics</i> , 2014, 134, 361-372.	1.0	217
11	A review on the taste masking of bitter APIs: hot-melt extrusion (HME) evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 145-156.	0.9	57
12	Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22368-22401.	1.8	135
13	Safety of Excipients in Pediatric Formulations – A Call for Toxicity Studies in Juvenile Animals?. <i>Children</i> , 2015, 2, 191-197.	0.6	16
15	The STEP database through the end-users eyes – USABILITY STUDY. <i>International Journal of Pharmaceutics</i> , 2015, 492, 316-331.	2.6	17
16	Excipients in Pediatric Formulations: Biopharmaceutical and Toxicological Considerations. , 2015, , 497-519.		2
17	Formulations for children: problems and solutions. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 405-418.	1.1	130
18	Mind the Gap! A Journey towards Computational Toxicology. <i>Molecular Informatics</i> , 2016, 35, 294-308.	1.4	25
19	Evaluation of the ability of powdered milk to produce minitablets containing paracetamol for the paediatric population. <i>Chemical Engineering Research and Design</i> , 2016, 110, 171-182.	2.7	11

#	ARTICLE	IF	CITATIONS
20	Oral dosage form administration practice in children under 6 years of age: A survey study of paediatric nurses. <i>International Journal of Pharmaceutics</i> , 2016, 511, 855-863.	2.6	9
21	Moving toward a paradigm shift in the regulatory requirements for pediatric medicines. <i>European Journal of Pediatrics</i> , 2016, 175, 1881-1891.	1.3	14
22	Pharmaceutical excipients " quality, regulatory and biopharmaceutical considerations. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 87, 88-99.	1.9	88
23	Reflection on the Pharmaceutical Formulation Challenges Associated with a Paediatric Investigation Plan for an Off-Patent Drug. <i>AAPS PharmSciTech</i> , 2017, 18, 250-256.	1.5	14
24	Paediatric Medicines: Regulatory and Scientific Issues. <i>Drug Research</i> , 2017, 67, 377-384.	0.7	3
25	Patient-centered drug delivery and its potential applications for unmet medical needs. <i>Therapeutic Delivery</i> , 2017, 8, 775-790.	1.2	8
26	European Paediatric Formulation Initiative (EuPFI)"Formulating Ideas for Better Medicines for Children. <i>AAPS PharmSciTech</i> , 2017, 18, 257-262.	1.5	30
27	The Role of Carrageenan and Carboxymethylcellulose in the Development of Intestinal Inflammation. <i>Frontiers in Pediatrics</i> , 2017, 5, 96.	0.9	93
29	Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients. <i>International Journal of Pharmaceutics</i> , 2018, 536, 563-569.	2.6	27
30	Furosemide ethanol-free oral solutions for paediatric use: formulation, HPLC method and stability study. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 144-149.	0.5	7
31	Paediatric Needs: Challenge and Opportunities for Hospital Pharmacists. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2018, 3, 47-48.	0.4	0
32	Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. <i>Pharmaceutical Medicine</i> , 2018, 32, 251-258.	1.0	26
33	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2231-2241.	1.1	18
34	Physicochemical and microbiological stability of two new oral liquid formulations of clonidine hydrochloride for pediatric patients. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 465-478.	1.1	7
35	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. <i>Pharmaceutics</i> , 2019, 11, 567.	2.0	27
36	Pediatric Formulations: Knowledge Gaps Limiting the Expedited Preclinical to Clinical Translation in Children. <i>AAPS PharmSciTech</i> , 2019, 20, 73.	1.5	6
37	Current Developments in Excipient Science. , 2019, , 29-83.		31
38	Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound " A promising starting point for future PUMA applications. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 156, 11-19.	2.0	19

#	ARTICLE	IF	CITATIONS
39	&lt;p&gt;Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations&lt;/p&gt;. International Journal of General Medicine, 2020, Volume 13, 1051-1066.	0.8	25
40	Importance of Pharmacotherapeutic Follow-Up in Odontopediatrics. Open Journal of Stomatology, 2021, 11, 1-13.	0.1	0
41	Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies. AAPS PharmSciTech, 2021, 22, 40.	1.5	2
42	Biopharmaceutical considerations in the pediatric and geriatric formulation development. , 2021, , 109-144.		0
43	Excipients in the Paediatric Population: A Review. Pharmaceutics, 2021, 13, 387.	2.0	51
44	Pediatric formulation development â€œ Challenges of today and strategies for tomorrow: Summary report from Mâ€™CERSI workshop 2019. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 164, 54-65.	2.0	6
46	Paediatric Solid Formulations. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 153-170.	0.2	4
47	Propylene Glycol in Neonates: Never Prescribed, Frequently Administered, Hardly Evaluated. , 2012, 02, .		7
48	The Clinical Relevance of Pediatric Formulations. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 69-85.	0.2	0
49	Evaluating the Taste Masking Ability of Two Novel Dispersible Tablet Platforms Containing Zinc Sulfate and Paracetamol Reconstituted in a Breast Milk Substitute. Pharmaceutics, 2022, 14, 420.	2.0	3
50	The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and Region. Children, 2022, 9, 453.	0.6	8
51	Paediatric oral formulations: Why don't our kids have the medicines they need?. British Journal of Clinical Pharmacology, 2022, 88, 4337-4348.	1.1	9
52	Palatability assessment of oral dosage forms for companion animals: A systematic review. Journal of Drug Delivery Science and Technology, 2022, 77, 103841.	1.4	1
58	Juvenile Testing to Support Clinical Trials in Pediatric Population. , 2024, , 271-284.		0